- Consumer Products
- Latest 27.56
- Currency US$
- Change 0.12
- Percent Change 0.437 %
- Volume 259,369
- Mon May 20, 2013 4:00 PM EDT NASDAQ data delayed 15 minutes.
12 months ended Mar 31, 2013.
Trailing 12 month results shown above.
All data is in U.S. dollars.
|Earnings||May 6||$-0.31||Aug 5||$-0.34|
12 months ended May 21, 2013.
A look at major corporate events and financial announcements that are coming up.
About the Company
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is applying its therapeutic expertise in RNAi to address significant medical needs, many of which cannot effectively be addressed with small molecules or antibodies, the current major classes of drugs. Alnylam is building a pipeline of RNAi therapeutics; its lead program is in Phase I human clinical trials for the treatment of respiratory syncytial virus infection, which is the leading cause of hospitalization in infants in the U.S. The company's leadership position in fundamental patents, technology, and know-how relating to RNAi has enabled it to form major alliances with leading companies including Merck, Medtronic, Novartis, and Biogen Idec.